SCHEMBL13199036

SCHEMBL13199036

NCC(=O)OCc1ccc(-c2nn(Cc3ccccc3)c3ccccc23)o1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 10/20 0.69
CYP2D6 P10635 3/20 0.66
CYP1A2 P05177 2/20 0.66
CYP3A4 P08684 2/20 0.66
KDM4E B2RXH2 2/20 0.66
ALDH1A1 P00352 2/20 0.66
LMNA P02545 2/20 0.66
HPGD P15428 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
HSD17B10 Q99714 2/20 0.66
NPC1 O15118 1/20 0.66
GMNN O75496 1/20 0.66
TP53 P04637 1/20 0.66
MAPT P10636 1/20 0.66
CYP2C9 P11712 1/20 0.66
ALOX15 P16050 1/20 0.66
NFKB1 P19838 1/20 0.66
MAPK1 P28482 1/20 0.66
CYP2C19 P33261 1/20 0.66
RAB9A P51151 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199041 0.93 PDE5A (0.67) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL16267521 0.92 PDE5A (0.71) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL5110534 0.89 PDE5A (0.67) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL3071011 0.88 PDE5A (0.74) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL5140293 0.84 PDE5A (0.60) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL5116858 0.83 PDE5A (0.71) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL27630149 0.82 PDE5A (0.67) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL3071869 0.82 PDE5A (0.77) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL6356567 0.82 PDE5A (0.72) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL4849350 0.82 PDE5A (1.00) PDE5ACYP2D6CYP1A2CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767707-B2 Fused pyrazolyl compounds having an aminoalkylcarbonyl group YUNG SHIN PHARM. IND. CO., LTD. (TW) 2010-08-03 US disclosed
US-7767707-B2 Fused pyrazolyl compounds having an aminoalkylcarbonyl group YUNG SHIN PHARM. IND. CO., LTD. (TW) 2010-08-03 US disclosed
US-20090131681-A1 Novel fused pyrazolyl compounds having an aminoalkylcarbonyl group YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-05-21 US disclosed
US-20090131681-A1 Novel fused pyrazolyl compounds having an aminoalkylcarbonyl group YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131681-A1 Novel fused pyrazolyl compounds having an aminoalkylcarbonyl group H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCOR1, RB1 PDE5A 4348/4885CYP2D6 1146/4885CYP1A2 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.